Evolution of pulmonary surfactants for the treatment of neonatal respiratory distress syndrome and paediatric lung diseases.
This review documents the evolution of surfactant therapy, beginning with observations of surfactant deficiency in respiratory distress syndrome, the basis of exogenous surfactant treatment and the development of surfactant-containing novel peptides patterned after SP-B. We critically analyse the molecular interactions of surfactant proteins and phospholipids contributing to surfactant function.


CONCLUSIONS
Peptide-containing surfactant provides clinical efficacy in the treatment of respiratory distress syndrome and offers promise for treating other lung diseases in infancy.
Mazela
Jan
J
Department of Neonatology, Poznan University of Medical Sciences, Poznan, and Polish Mother's Memorial Hospital Research Institute, Lodz, Poland.
Merritt
T Allen
TA
Gadzinowski
Janusz
J
Sinha
Sunil
S
D002986:Clinical Trials as Topic; D004338:Drug Combinations; D005233:Fatty Alcohols / Q000627:therapeutic use; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D007231:Infant, Newborn; D015931:Intensive Care, Neonatal / Q000639:trends; D008171:Lung Diseases / Q000188:drug therapy; D010455:Peptides / Q000627:therapeutic use; D010715:Phosphatidylglycerols / Q000627:therapeutic use; D010743:Phospholipids / Q000627:therapeutic use; D011506:Proteins / Q000627:therapeutic use; D011650:Pulmonary Alveoli / Q000502:physiology; D037661:Pulmonary Surfactant-Associated Proteins / Q000502:physiology / Q000627:therapeutic use*; D011663:Pulmonary Surfactants / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D012127:Respiratory Distress Syndrome, Newborn / Q000188:drug therapy*
D004338:Drug Combinations; D005233:Fatty Alcohols; D010455:Peptides; D010715:Phosphatidylglycerols; D010743:Phospholipids; D011506:Proteins; D037661:Pulmonary Surfactant-Associated Proteins; D011663:Pulmonary Surfactants; C502722:lucinactant